TY  - JOUR
AU  - Chibaudel, Benoist
AU  - Henriques, Julie
AU  - Rakez, Manel
AU  - Brenner, Baruch
AU  - Kim, Tae Won
AU  - Martinez-Villacampa, Mercedes
AU  - Gallego-Plazas, Javier
AU  - Cervantes, Andres
AU  - Shim, Katharine
AU  - Jonker, Derek
AU  - Guerin-Meyer, Veronique
AU  - Mineur, Laurent
AU  - Banzi, Chiara
AU  - Dewdney, Alice
AU  - Dejthevaporn, Thitiya
AU  - Bloemendal, Haiko J
AU  - Roth, Arnaud
AU  - Moehler, Markus
AU  - Aranda, Enrique
AU  - Van Cutsem, Eric
AU  - Tabernero, Josep
AU  - Schmoll, Hans-Joachim
AU  - Hoff, Paulo M
AU  - André, Thierry
AU  - de Gramont, Aimery
PY  - 2020
DO  - 10.1001/jamanetworkopen.2020.20425
UR  - https://hdl.handle.net/10668/25321
T2  - JAMA network open
AB  - In the pivotal Bevacizumab-Avastin Adjuvant (AVANT) trial, patients with high-risk stage II colon cancer (CC) had 5-year and 10-year overall survival (OS) rates of 88% and 75%, respectively, with adjuvant fluorouracil and oxaliplatin-based...
LA  - en
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bevacizumab
KW  - Capecitabine
KW  - Chemotherapy, Adjuvant
KW  - Colonic Neoplasms
KW  - Disease-Free Survival
KW  - Female
KW  - Fluorouracil
KW  - Humans
KW  - Leucovorin
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Organoplatinum Compounds
KW  - Oxaloacetates
KW  - Proportional Hazards Models
KW  - Treatment Outcome
TI  - Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
TY  - research article
VL  - 3
ER  -